Chapter 38 Toxin Purification
"The second phase involves the reactor itself," Lynn said calmly.
"But that requires your cooperation, and it concerns proprietary core technology."
A brief pause.
"We'll complete phase one first."
Tony Stark considered it for several seconds.
Then nodded once.
"Fine."
"Remove your shirt. The reactor needs to remain exposed."
Tony paused briefly while unbuttoning it.
Not from embarrassment—
From instinct.
The arc reactor was simultaneously his greatest achievement and his greatest vulnerability.
Life support system.
Power source.
Target.
But he removed the shirt anyway.
The circular reactor embedded in the center of his chest emitted a steady blue glow.
Around it—
Old surgical scarring from the original implantation in Afghanistan.
The diagnostic interface expanded immediately in Lynn's vision.
The reactor appeared as a semi-transparent structural model.
Layered.
Precise.
At the center—
The palladium core.
Bright.
Burning like a contained artificial star.
Surrounding it—
The electrolyte interface layer.
And across that layer—
Microscopic fractures.
Spiderweb-like nanoscale cracking distributed throughout the thermal boundary surface.
Exactly as predicted.
But the reactor wasn't the only problem.
Palladium toxicity had already spread throughout Tony's body.
Under the system overlay, toxic accumulation appeared as darkened pathways moving along the vascular network.
Highest concentration zones:
Liver.
Kidneys.
Peripheral nervous system.
The tremor in Tony's right hand—
Peripheral neural impairment caused by chronic heavy-metal exposure.
Lynn began preparing the treatment.
Chelation therapy.
But not standard chelation.
Conventional methods such as DMSA or EDTA lacked specificity for palladium ions.
They removed beneficial trace metals as well—
Copper.
Zinc.
Magnesium.
Inefficient.
Using the chemical modeling capability derived from Batman's knowledge base, combined with the reactor parameters Tony had unintentionally revealed earlier, Lynn constructed a superior compound.
Three-component structure:
A modified dimercaprol derivative as the primary chelating agent.
A targeted B-complex coenzyme to stabilize normal trace-metal metabolism.
And—
A controlled carbon nanotube suspension to accelerate renal excretion efficiency.
Dosage precision reached milligram-level calibration.
Every variable accounted for:
Weight.
Organ function.
Current toxicity level.
Projected leakage rate.
Tony watched the entire process carefully.
His attention never left Lynn's hands.
Even without formal specialization in chemistry, Tony understood precision when he saw it.
And this—
Was not the movement pattern of an inexperienced twenty-two-year-old dropout.
"How much more effective is this compared to standard chelation therapy?" Tony asked.
"Approximately four times."
Tony's eyes narrowed slightly.
"Four?"
"What's your theoretical basis?"
"Not theory," Lynn replied.
"Calculation."
"I estimate your current serum palladium concentration at roughly eighty micrograms per liter."
"Seventy-eight," Tony corrected automatically.
"Seventy-eight," Lynn repeated evenly.
"At that concentration, conventional DMSA protocols remove approximately four to six percent of systemic palladium load per treatment cycle."
"My formulation should achieve fifteen to twenty percent."
Tony looked at the suspension again.
"Because of the nanotubes."
"You noticed."
"The surface-area ratio explains the adsorption efficiency," Tony said.
"But how are you preventing tubular accumulation inside the kidneys?"
"Nanotube length remains below two hundred nanometers."
"That prevents retention by renal tubular epithelial structures."
"Additionally, PEG surface modification reduces protein adhesion and maintains high excretion efficiency."
Silence.
Two seconds.
"Where did you learn this?"
"Self-study."
Tony repeated the phrase quietly.
"Self-study."
Three minutes later—
The injection began.
Lynn inserted an ultra-fine intravenous needle into the median cubital vein of Tony's left arm.
Precise.
Minimal discomfort.
The chelation compound entered the bloodstream slowly.
Seven minutes later—
Tony felt the first effect.
"There's heat," he said.
"Starting near the reactor."
"Spreading outward."
"The chelating agents are binding with circulating palladium ions," Lynn explained.
"Partial exothermic reaction."
The sensation continued for roughly twenty minutes.
Throughout the process, Lynn monitored real-time internal metrics through the diagnostic overlay.
Palladium concentration steadily declined.
Thirty minutes later—
Infusion complete.
Tony looked down at his neck.
In recent months, faint dark vascular lines had appeared beneath the skin from systemic toxicity.
Now—
They had faded significantly.
"How do you feel?" Lynn asked.
Tony raised his right hand.
No tremor.
His fingers opened.
Closed.
Opened again.
Movement smooth.
Stable.
"You repaired the nerve damage too?"
"No."
Lynn removed the IV line carefully.
"The symptoms improved because toxin concentration dropped."
"Structural nerve recovery still requires time."
Tony stared at his hand silently for several seconds.
"What's my current level?"
"Approximately twenty-six micrograms per liter."
"Below immediate danger thresholds."
"But the reactor is still leaking," Lynn continued.
"At the current rate, concentration will return to hazardous levels within two to three months."
"So either I come back for another detoxification…"
Tony looked toward the reactor.
"Or solve the actual problem before then."
"Correct."
"Phase two?"
"We can begin immediately."
Tony didn't hesitate.
He pulled his shirt back on loosely without buttoning it.
The reactor remained exposed.
"You said you could improve the reactor."
"How?"
Lynn moved a chair closer and sat opposite him.
Distance—
Minimal.
At this range, the diagnostic overlay achieved maximum structural precision.
Every layer of the reactor became sharply defined:
Outer shell.
Seal structures.
Electrolyte interface layer.
Palladium core.
Energy output channels.
Bio-interface integration points.
"Your reactor has three optimization zones," Lynn said.
Tony raised an eyebrow.
"First—the thermal feedback system."
"You're currently sampling temperature fluctuations at approximately two hundred hertz."
Tony's eyes sharpened immediately.
"The reactor core fluctuates on a sub-millisecond scale," Lynn continued.
"Approximately 0.8 to 1.2 milliseconds per cycle."
"A 200 Hz feedback rate misses critical thermal spikes."
He pointed toward the interface layer.
"Those missed peaks are the primary cause of nanoscale stress fractures."
"If you increase thermal feedback frequency beyond 500 Hz, palladium leakage should decrease by at least forty percent."
Tony's expression changed.
Not skepticism.
Recognition.
The expression of someone realizing an overlooked flaw in his own system.
"Two hundred hertz was inherited from the original prototype architecture," Tony said slowly.
Then faster—
"Why the hell didn't I rework that earlier?"
Visit /ShiroTL for more chapters.